Cosentyx Cost in 2026: Prices & How to Save
Cosentyx Cost in 2026: Prices & How to Save
Your dermatologist writes the prescription, the specialty pharmacy calls, and the number they read out is somewhere north of $8,000. For one month. That reaction — the pause, the "say that again" — is the most common first experience people have with Cosentyx pricing.
The Cosentyx cost problem is real, and the numbers below are the actual ones as of August 2026. What most pricing pages leave out is the part that hurts worst: your first year costs meaningfully more than every year after it, because of how the drug is loaded.
At a glance
- The list price for Cosentyx is $8,492.03 per four-week self-injection package as of January 2026, and $4,489.34 per IV infusion
- Retail cash prices at US pharmacies run roughly $7,200 to $9,000 per package depending on where you fill it
- Novartis sells Cosentyx directly to cash-paying patients for $1,837.22 (150 mg) or $3,674.44 (300 mg) per dose
- Five weekly loading doses mean year one runs about three doses higher than a maintenance year — roughly $25,000 more at list price
- No secukinumab biosimilar is FDA-approved yet; the core US patent runs to about 2029
How much does Cosentyx cost without insurance in 2026?
Novartis publishes the list price directly, which is more than most manufacturers do. As of January 2026, that price is $8,492.03 for a four-week self-injection package and $4,489.34 for a single intravenous infusion in someone weighing 165 to 310 pounds.
List price is not the same as what a pharmacy charges you at the counter. Cash prices at US retail and specialty pharmacies in 2026 land in this range:
| Where you fill it | Approximate cash price per package |
|---|---|
| Lowest advertised retail | ~$7,189 |
| Walgreens / Walgreens Specialty | ~$8,240 |
| Sam's Club | ~$8,480 |
| Costco | ~$9,023 |
| Novartis direct-to-patient (300 mg dose) | $3,674.44 |
| Novartis direct-to-patient (150 mg dose) | $1,837.22 |
Two things stand out in that table.
The first is the spread. Roughly $1,800 separates the cheapest and most expensive retail counters for the identical product. If you're paying cash and you didn't call three pharmacies, you probably overpaid.
The second is bigger. Novartis began selling Cosentyx directly to people paying out of pocket, and the direct price for a 150 mg dose is $1,837.22 — about 78% below the list price for the same package. For a 300 mg dose it's $3,674.44, roughly 57% below list. Almost no one filling a prescription at a retail counter knows this price exists.
Why your first year costs more than every year after
Here's the part that pricing pages skip.
Cosentyx doesn't start at a monthly rhythm. For plaque psoriasis and hidradenitis suppurativa, the FDA-approved regimen is 300 mg at weeks 0, 1, 2, 3, and 4 — five doses in the first month — and only then does it settle into every four weeks. Those loading doses are full-price doses.
Count the calendar for plaque psoriasis:
| Doses in the year | At Novartis direct price (300 mg) | At list price | |
|---|---|---|---|
| Year one (with loading) | 16 | ~$58,791 | ~$135,872 |
| Every year after | 13 | ~$47,768 | ~$110,396 |
That's roughly an $11,000 difference at the direct cash price, and about $25,500 at list. If you budgeted for "$8,500 a month" and planned for twelve payments, year one will be about four payments heavier than you expected.
Worth asking your prescriber whether your condition actually calls for loading. Ankylosing spondylitis and non-radiographic axial spondyloarthritis can be dosed at 150 mg every four weeks with or without a loading regimen — and skipping loading, when clinically appropriate, removes three doses from your first-year bill.
Savings tip: At list price, the 150 mg and 300 mg packages cost the same — $8,492.03. At the Novartis cash price, the 150 mg dose costs exactly half of the 300 mg dose. If your prescriber has you on 150 mg, paying cash is where that lower dose finally shows up as a lower bill.
Cosentyx cost by condition
Dose depends on what you're treating, and dose is most of what drives your annual cost. These are the approved adult regimens:
| Condition | Typical dose | Doses in year one | Approx. year-one cost at direct cash price |
|---|---|---|---|
| Plaque psoriasis | 300 mg, loading then every 4 weeks | 16 | ~$58,791 |
| Hidradenitis suppurativa | 300 mg, loading then every 4 weeks | 16 | ~$58,791 |
| Psoriatic arthritis | 150 mg every 4 weeks (300 mg for some) | 13–16 | ~$23,884–$29,396 |
| Ankylosing spondylitis | 150 mg every 4 weeks, loading optional | 13–16 | ~$23,884–$29,396 |
| Non-radiographic axSpA | 150 mg every 4 weeks, loading optional | 13–16 | ~$23,884–$29,396 |
Someone with ankylosing spondylitis on 150 mg without loading pays roughly 40% of what a plaque psoriasis patient on 300 mg with loading pays. Same drug, same year, wildly different bill. When you read "Cosentyx costs $8,492 a month" on a pricing site, that number is doing a lot of averaging.
Dose can also change mid-treatment. Ankylosing spondylitis patients who don't respond adequately at 150 mg may be moved to 300 mg, which doubles the drug cost from that point forward. Ask what the escalation plan is before you start, not after.
Self-injection versus IV infusion: two different bills
Cosentyx comes as a pen or prefilled syringe you use at home, and as an intravenous infusion given at a clinic or infusion center every four weeks. The IV form is approved for psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis, and it's dosed by body weight.
The list price for a single infusion is $4,489.34 for someone between 165 and 310 pounds. Lighter patients get less drug and pay less; heavier patients pay more.
That number is only part of the bill. IV Cosentyx is administered by a provider, which usually means the drug is billed through your medical benefit rather than your pharmacy benefit, and the facility adds its own infusion and administration charges on top. Those facility fees vary enormously — a hospital outpatient department typically charges several times what an independent infusion center does for the same 30-minute infusion.
If you're paying cash and your prescriber offers you either form, ask for the all-in quote on both. The self-injection route removes the facility fee entirely.
Is there a generic or biosimilar for Cosentyx?
Not in the United States. Not yet.
Cosentyx is a biologic, so it won't get a conventional generic — it would get a biosimilar, and as of August 2026 the FDA hasn't approved one. Secukinumab's core US patent runs to roughly January 2029, with secondary patents that could stretch protection further.
Development is moving, though. Celltrion's CT-P55 is the furthest along: the company filed for approval with Health Canada on June 1, 2026, in South Korea that same month, and with the European Medicines Agency on July 24, 2026. A US filing is planned. Bio-Thera's BAT2306 is also in phase 3 trials.
What that timeline means practically: a meaningful drop in secukinumab prices is a 2029-or-later event in the US, and Canada and Europe will likely see biosimilar competition first. Anyone budgeting for Cosentyx should plan around today's prices rather than waiting for a cheaper version to arrive.
What the alternatives actually cost
Cosentyx isn't the only IL-17 or systemic option, and the price gaps between classes are enormous. This is a conversation for your rheumatologist or dermatologist — but it helps to walk in knowing the numbers.
| Treatment | Class | Rough US cash cost |
|---|---|---|
| Cosentyx (secukinumab) | IL-17A inhibitor | ~$7,200–$9,000/month retail |
| Humira and adalimumab biosimilars | TNF inhibitor | Biosimilars run far below brand |
| Otezla (apremilast) | Oral PDE4 inhibitor | Oral, no injection or infusion fees |
| Methotrexate | Conventional DMARD | Generic — a small fraction of biologic pricing |
| Cyclosporine | Systemic immunosuppressant | Generic |
Adalimumab biosimilars are the clearest example of what happens when competition arrives. Multiple biosimilars entered the US market and brought real price movement with them — which is exactly what secukinumab is still waiting for. Our Humira cost breakdown has the current adalimumab numbers.
Methotrexate deserves a mention that biologic-focused content usually skips. It's decades old, it's generic, it costs a rounding error compared to any of the injectables above, and for some people with psoriatic arthritis it works. It isn't right for everyone and it carries real monitoring requirements. But if cost is the thing keeping you from treatment at all, it's a legitimate conversation to have.
Never stop or switch a biologic on your own. Flares after abrupt discontinuation can be severe, and some people who stop an IL-17 inhibitor respond less well when they restart it.
How to lower your Cosentyx cost
Call for the direct cash price before you fill anywhere. The Novartis direct-to-patient price is published — $1,837.22 for 150 mg, $3,674.44 for 300 mg per dose. Compare that against whatever your pharmacy quotes before you hand over a card.
Price at least three pharmacies. The $1,800 spread between the cheapest and most expensive US counters is free money if you make the calls.
Ask whether loading is necessary for your indication. For axial spondyloarthritis, a no-loading regimen is an approved option, and it removes three doses from year one.
If you're on IV, price the site of care separately from the drug. Hospital outpatient infusion suites and independent infusion centers charge very different facility fees for the identical service.
Compare cash-pay networks against retail. Cash-pay services process claims outside the insurance system and often price high-cost medications well below US retail. Cosentyx isn't currently in the CanAmerica Plus catalog, but several of the alternatives above are, and it's worth searching the catalog for whatever your prescriber lands on.
Savings tip: If your prescriber is choosing between two biologics that are clinically reasonable for you, ask them to check both prices before writing the prescription. That five-minute conversation is worth more than every discount tactic on this page combined.
The bottom line
Cosentyx costs $8,492.03 per four-week package at list price in 2026, and roughly $7,200 to $9,000 in cash at US pharmacies — but the Novartis direct-to-patient price cuts that to $1,837.22 or $3,674.44 per dose depending on your strength. Your first year runs about three doses higher than every year after because of loading.
No biosimilar is coming before 2029 in the US, so today's prices are the prices to plan around. Get quotes from several pharmacies, ask your prescriber about dose and loading, and price the alternatives before you commit.
Frequently asked questions
How much does Cosentyx cost per month without insurance?
The list price is $8,492.03 per four-week self-injection package as of January 2026. Retail cash prices run roughly $7,189 to $9,023 depending on the pharmacy. Novartis also sells directly to cash payers at $1,837.22 per 150 mg dose or $3,674.44 per 300 mg dose.
Is there a generic for Cosentyx?
No. Cosentyx is a biologic, so it would get a biosimilar rather than a generic, and the FDA hasn't approved a secukinumab biosimilar as of August 2026. Celltrion's CT-P55 has been filed in Canada, Korea, and Europe, with a US filing planned. The core US patent runs to about 2029.
Why is Cosentyx so expensive?
It's a monoclonal antibody produced in living cell cultures, which is far costlier to manufacture than a small-molecule pill. It's also still under patent protection with no competing version on the US market, so there's nothing pushing the price down.
Does Medicare cover Cosentyx?
Coverage depends on the form. Self-injected Cosentyx is generally handled under Part D prescription drug coverage, while IV infusions given in a clinic are typically billed under Part B as a provider-administered drug. Your out-of-pocket cost differs substantially between the two, so check which applies before choosing a form.
Is 150 mg cheaper than 300 mg?
At list price, no — both package strengths are priced at $8,492.03. Through the Novartis direct cash channel, yes: 150 mg costs $1,837.22 per dose versus $3,674.44 for 300 mg, exactly half.
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment. Pricing information is current as of the publication date but may change. Verify pricing directly before making purchasing decisions.
